근위축성측삭경화증 환자에서 자가 골수유래 중간엽줄기세포치료의 유효성 및 안전성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현영 | - |
dc.contributor.author | 백진영 | - |
dc.contributor.author | 박희경 | - |
dc.contributor.author | 최미란 | - |
dc.contributor.author | 윤현수 | - |
dc.contributor.author | 김경숙 | - |
dc.contributor.author | 김승현 | - |
dc.date.accessioned | 2022-12-20T22:17:48Z | - |
dc.date.available | 2022-12-20T22:17:48Z | - |
dc.date.created | 2022-09-19 | - |
dc.date.issued | 2009-05 | - |
dc.identifier.issn | 1225-7044 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/176780 | - |
dc.description.abstract | Background: This study was performed to investigate the efficacy and safety of intrathecal autologous bone marrowderived mesenchymal stem cells (MSCs) treatment for patients with ALS. Methods: After a lead-in period for 3 months, 22 patients were treated with MSCs twice at an interval of 1 month. After initial MSCs injection, all patients were followed up for 3 months and their disease course, clinical characteristics were assessed. Disease status of patients were analyzed with ALS functional rating scale-revised (ALSFRS-R) for primary outcome measure, and additional clinical findings after treatment were all collected for secondary outcome measure and safety. Age and disease-duration matched patients with ALS were selected as a control group. Results: During the follow-up period, MSCs treatment yielded a significant lesser change of ALSFRS-R score, compared to control group (1.54 vs 3.56, p<0.01). Moreover, the slop of decline of ALSFRS-R was significantly lower during the follow-up period, compared to the lead-in period in MSCs treatment group (2.68 vs 1.54, p=0.04), whereas the slopes during the two periods were not different in the control group (3.15 vs 3.56, p=0.37). MSCs treatment was well tolerated except for occurrences of transient headache, low back pain, and myalgia. Conclusions: Our results show that intrathecal MSCs injection can slow disease progression and might be used as a disease modifying modality as an alternative treatment choice in patients with ALS. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한신경과학회 | - |
dc.title | 근위축성측삭경화증 환자에서 자가 골수유래 중간엽줄기세포치료의 유효성 및 안전성 | - |
dc.title.alternative | Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients With Amyotrophic Lateral Sclerosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 김현영 | - |
dc.contributor.affiliatedAuthor | 김승현 | - |
dc.identifier.bibliographicCitation | 대한신경과학회지, v.27, no.2, pp.163 - 169 | - |
dc.relation.isPartOf | 대한신경과학회지 | - |
dc.citation.title | 대한신경과학회지 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 163 | - |
dc.citation.endPage | 169 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001337364 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Autologous bone marrow-derived mesenchymal stem cell | - |
dc.subject.keywordAuthor | Amyotrophic lateral sclerosis | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Safety | - |
dc.identifier.url | https://www.jkna.org/journal/view.php?number=5703 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.